GeNeuro builds a therapeutic product pipeline for disorders of the nervous system with high unmet medical needs. GeNeuro’s therapeutic approach is to act upstream of the pathological process of the disease, thus increasing efficacy and safety. The company’s goal is to optimize the management of the disease, including the treatment, the diagnostic tools and the patient’s follow-up.
Multiple Sclerosis is GeNeuro’s most advanced indication. The lead compound is a therapeutic monoclonal antibody for the treatment of Multiple Sclerosis. GeNeuro’s goal is to provide a drug with a therapeutic advantage over existing drugs in Multiple Sclerosis, which mainly delay neurological damages and disability.
Schizophrenia is GeNeuro's second indication.
GeNeuro also targets other neurological and autoimmune diseases.
GeNeuro SA is a member of the Swiss Biotech Association, a member of the BioAlps community and has the CTI (Commission for Technology and Innovation) start-up label.
GeNeuro Innovation SAS is member of the French Lyon Biopole.